Sarah Mangiafico
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sarah Mangiafico.
European Heart Journal | 2013
Sarah Mangiafico; Lisa C. Costello-Boerrigter; Ingrid A. Andersen; Alessandro Cataliotti; John C. Burnett
Hypertension and heart failure (HF) are common diseases that, despite advances in medical therapy, continue to be associated with high morbidity and mortality. Therefore, innovative therapeutic strategies are needed. Inhibition of the neutral endopeptidase (NEPinh) had been investigated as a potential novel therapeutic approach because of its ability to increase the plasma concentrations of the natriuretic peptides (NPs). Indeed, the NPs have potent natriuretic and vasodilator properties, inhibit the activity of the renin-angiotensin-aldosterone system, lower sympathetic drive, and have antiproliferative and antihypertrophic effects. Such potentially beneficial effects can be theoretically achieved by the use of NEPinh. However, studies have shown that NEPinh alone does not result in clinically meaningful blood pressure-lowering actions. More recently, NEPinh has been used in combination with other cardiovascular agents, such as angiotensin-converting enzyme inhibitors, and antagonists of the angiotensin receptor. Another future possible combination would be the use of NEPinh with NPs or their newly developed chimeric peptides. This review summarizes the current knowledge of the use and effects of NEPinh alone or in combination with other therapeutic agents for the treatment of human cardiovascular disease such as HF and hypertension.
Journal of the American College of Cardiology | 2012
Fima Macheret; Denise M. Heublein; Lisa C. Costello-Boerrigter; Guido Boerrigter; Paul M. McKie; Diego Bellavia; Sarah Mangiafico; Yasuhiro Ikeda; Kent R. Bailey; Christopher G. Scott; Sharon M. Sandberg; Horng H. Chen; Lorenzo Malatino; Margaret M. Redfield; Richard J. Rodeheffer; John C. Burnett; Alessandro Cataliotti
OBJECTIVES This study sought to investigate plasma levels of circulating cardiac natriuretic peptides, atrial natriuretic peptide (ANP) and B-type or brain natriuretic peptide (BNP), in the general community, focusing on their relative differences in worsening human hypertension. BACKGROUND Although ANP and BNP are well-characterized regulators of blood pressure in humans, little is known at the population level about their relationship with hypertension. The authors hypothesized that hypertension is associated with a lack of activation of these hormones or their molecular precursors. METHODS The study cohort (N = 2,082, age >45 years) was derived from a random sample from Rochester, Minnesota, and each subject had a medical history, clinical examination, and assessment of different plasma forms of ANP and BNP. Patients were stratified by blood pressure. Multivariable linear regression was used to assess differences in natriuretic peptide levels in worsening hypertension. RESULTS Compared to normotensive, BNP(1-32) and N-terminal proBNP(1-76) (NT-proBNP(1-76)) were significantly decreased in pre-hypertension (p < 0.05), with BNP(1-32) significantly decreased in stage 1 as well (p < 0.05). Although proBNP(1-108) remained unchanged, the processed form was significantly increased only in stage 2 hypertension (p < 0.05). ANP(1-28) remained unchanged, while NT-ANP(1-98) was reduced in pre-hypertension (p < 0.05). CONCLUSIONS The authors demonstrated the existence of an impaired production and/or release of proBNP(1-108) along with a concomitant reduction of BNP(1-32) and NT-proBNP(1-76) in the early stages of hypertension, with a significant elevation only in stage 2 hypertension. Importantly, they simultaneously demonstrated a lack of compensatory ANP elevation in advanced hypertension.
American Journal of Physiology-regulatory Integrative and Comparative Physiology | 2012
Fernando L. Martin; Paul M. McKie; Alessandro Cataliotti; S. Jeson Sangaralingham; Josef Korinek; Brenda K. Huntley; Elise A. Oehler; Gerald E. Harders; Tomoko Ichiki; Sarah Mangiafico; Karl A. Nath; Margaret M. Redfield; Horng H. Chen; John C. Burnett
Impaired renal function with loss of nephron number in chronic renal disease (CKD) is associated with increased cardiovascular morbidity and mortality. However, the structural and functional cardiac response to early and mild reduction in renal mass is poorly defined. We hypothesized that mild renal impairment produced by unilateral nephrectomy (UNX) would result in early cardiac fibrosis and impaired diastolic function, which would progress to a more global left ventricular (LV) dysfunction. Cardiorenal function and structure were assessed in rats at 4 and 16 wk following UNX or sham operation (Sham); (n = 10 per group). At 4 wk, blood pressure (BP), aldosterone, glomerular filtration rate (GFR), proteinuria, and plasma B-type natriuretic peptide (BNP) were not altered by UNX, representing a model of mild early CKD. However, UNX was associated with significantly greater LV myocardial fibrosis compared with Sham. Importantly, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining revealed increased apoptosis in the LV myocardium. Further, diastolic dysfunction, assessed by strain echocardiography, but with preserved LVEF, was observed. Changes in genes related to the TGF-β and apoptosis pathways in the LV myocardium were also observed. At 16 wk post-UNX, we observed persistent LV fibrosis and impairment in LV diastolic function. In addition, LV mass significantly increased, as did LVEDd, while there was a reduction in LVEF. Aldosterone, BNP, and proteinuria were increased, while GFR was decreased. The myocardial, structural, and functional alterations were associated with persistent changes in the TGF-β pathway and even more widespread changes in the LV apoptotic pathway. These studies demonstrate that mild renal insufficiency in the rat results in early cardiac fibrosis and impaired diastolic function, which progresses to more global LV remodeling and dysfunction. Thus, these studies importantly advance the concept of a kidney-heart connection in the control of myocardial structure and function.
BMC Pharmacology | 2011
Lisa C. Costello-Boerrigter; Guido Boerrigter; Sarah Mangiafico; Alessandro Cataliotti; John C. Burnett
Background Patients with congestive heart failure (HF) have symptomatic improvement with diuretic therapy, although with time diuretic resistance and renal dysfunction can occur. Cenderitide (also known as CD-NP), now in clinical trials in patients with HF, is a Mayo designed chimeric natriuretic peptide which, unlike the native natriuretic peptides (NPs) ANP, BNP and CNP, binds both to guanylyl cyclase (GC)-B and GC-A with greater affinity for GC-B. Cenderitide thus was designed to mediate more venodilation than arterial dilation via GC-B and so result in less hypotension than BNP or ANP, but unlike CNP also possess natriuretic and diuretic properties via GC-A activation. We tested the hypothesis that combining cenderitide with furosemide will produce increased diuresis and natriuresis compared to furosemide alone without causing excessive hypotension or renal dysfunction in experimental HF.
European Heart Journal | 2013
Ingrid A. Andersen; Sarah Mangiafico; Brenda K. Huntley; Guido Boerrigter; Gail J. Harty; Alessandro Cataliotti; John C. Burnett
Archive | 2012
Horng H. Chen; John C. Burnett; Tomoko Ichiki; Sarah Mangiafico; Karl A. Nath; Margaret M. Redfield; Josef Korinek; Brenda K. Huntley; Elise A. Oehler; L. Martin; Paul M. McKie; Alessandro Cataliotti; S. Jeson
Journal of Cardiac Failure | 2012
Ingrid A. Andersen; Sarah Mangiafico; Guido Boerrigter; Gail J. Harty; Alessandro Cataliotti; John C. Burnett
Journal of Cardiac Failure | 2012
Syed Ameenuddin; Elise A. Oehler; Sarah Mangiafico; Horng H. Chen
Journal of Cardiac Failure | 2012
Sarah Mangiafico; Diego Bellavia; Lisa C. Costello-Boerrigter; Guido Boerrigter; Gail J. Harty; Elise A. Oehler; Alessandro Cataliotti; Corrado Tamburino; John C. Burnett
Journal of Cardiac Failure | 2012
Alessandro Cataliotti; Jason M. Tonne; Sarah Mangiafico; John C. Burnett; Yasuhiro Ikeda